The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
about
Pharmacotherapy of vestibular and ocular motor disorders, including nystagmusGene, Stem Cell, and Alternative Therapies for SCA 1Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug DiscoveryUpdate on the pharmacotherapy of cerebellar and central vestibular disordersGenetic neurological channelopathies: molecular genetics and clinical phenotypes.Integration of modeling with experimental and clinical findings synthesizes and refines the central role of inositol 1,4,5-trisphosphate receptor 1 in spinocerebellar ataxiaThe physiological basis of therapies for cerebellar ataxiasWhich medication do I need to manage dizzy patients?SK2 channel expression and function in cerebellar Purkinje cellsCentral ocular motor disorders, including gaze palsy and nystagmus.Central oculomotor disturbances and nystagmus: a window into the brainstem and cerebellumButylidenephthalide blocks potassium channels and enhances basal tension in isolated guinea-pig trachea.Systematic regional variations in Purkinje cell spiking patterns.The first knockin mouse model of episodic ataxia type 2Simultaneous measurement of neural spike recordings and multi-photon calcium imaging in neuroblastoma cellsFlocculus Purkinje cell signals in mouse Cacna1a calcium channel mutants of escalating severity: an investigation of the role of firing irregularity in ataxia.4-aminopyridine does not enhance flocculus function in tottering, a mouse model of vestibulocerebellar dysfunction and ataxia.In vivo analysis of Purkinje cell firing properties during postnatal mouse development.A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxiasConsensus paper: management of degenerative cerebellar disorders.Large Genomic Deletions in CACNA1A Cause Episodic Ataxia Type 2The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.Kv1 channels and neural processing in vestibular calyx afferents.Selective and sustained α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor activation in cerebellum induces dystonia in mice.Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive ratsDifferential cerebellar GABAA receptor expression in mice with mutations in CaV2.1 (P/Q-type) calcium channels.Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 miceSelective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2Stress, caffeine and ethanol trigger transient neurological dysfunction through shared mechanisms in a mouse calcium channelopathyIn vivo analysis of cerebellar Purkinje cell activity in SCA2 transgenic mouse model.4-aminopyridine reverses ataxia and cerebellar firing deficiency in a mouse model of spinocerebellar ataxia type 6.Gain control of synaptic response function in cerebellar nuclear neurons by a calcium-activated potassium conductanceThe ataxic mouse as a model for studying downbeat nystagmusCerebellum and ocular motor control.What we know about the generation of nystagmus and other ocular oscillations: are we closer to identifying therapeutic targets?K(Ca)2 channels: novel therapeutic targets for treating alcohol withdrawal and escalation of alcohol consumption.Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research.Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia.
P2860
Q24595123-32C219E6-178F-448F-A1A6-A03ECABF5AC1Q26738497-F1022FB6-1D4B-4C0F-B85C-406E1CCF190EQ26744730-2D7868DB-A62A-4731-B753-E6419A4700C1Q26753139-B21730A2-016F-477D-B630-356292477737Q26777559-A09BA8DD-D924-451A-8380-081FAF84BB62Q26864714-7A5878FF-A93A-49D0-914C-24A0465F8E2AQ28075917-3E1EC4EC-7E2B-40B3-B4D7-9FDCC57B9763Q28300141-8A03EA2A-A82F-45A7-87A1-A36C3CCE8D53Q28573148-D8FE021E-CFBC-4C44-97A9-6EDFB5F08AB6Q30432497-FD9ACF7A-29FE-4FAF-A2CD-ED4CE9E8D49BQ30475787-38A52036-5E19-4D9D-A817-63A088D487F0Q33994041-8A0CB66E-7FD4-4958-820B-70C6B6E79A4DQ34075631-A87D589C-F552-49EB-A5C1-902F87756A0EQ34325294-4DC283EE-16D8-434F-8F9D-D37B748DA45BQ34497658-3CBA2417-E5CE-48BB-A735-BE8BFE8BAB0BQ34519145-92BF7916-31DD-40E8-AA25-7D92F24A5D04Q34603922-C7088F7B-D423-4138-8FC0-D358A6A6C8AAQ34980581-4191A186-54E0-4122-A5FB-BB59DD4918CDQ35104451-2CAA1EB9-8B3D-4650-B186-E064DCB8F63FQ35129909-91A416E6-8F52-41D3-842F-6F2131067693Q35204801-E8269AB1-287D-48C0-9BEA-361374155699Q35340099-0F238C97-29ED-4397-99AC-165D0F264DDBQ35671918-DD302091-B0CA-4701-ABA0-0AB0D49C7485Q35776832-0D897752-9C35-4804-9759-61A4FE0E4F0EQ35799859-B3FFECD1-7537-4787-81A7-FFDDFA4932C4Q35991521-5AAB3091-6501-4A1D-B5DF-4989BFAE04AFQ36315976-825EFDE8-A70F-4E09-8956-81284CD9DDC0Q36354944-A638F014-F459-4013-B981-058B6C2706BBQ36501625-280CA6FE-CD06-4D57-9EAD-555A4EED044DQ37042016-DAF4B4E8-54B7-4D7A-8F92-B75FB8AFF45EQ37067735-E52C45E9-815C-41D4-8196-EB8FBEF6C44AQ37146696-11FC431A-2C56-4A43-97F6-B48800EFD182Q37226571-6C3FB93C-7575-41DC-8E7C-3204FB238EDCQ37930408-F94CAD42-2106-4184-9E03-8E4968D3DB41Q37987065-8954532D-D6DB-4BB7-BC6D-829DFB63BE22Q37998692-B8196FF3-4737-4B58-A0DB-8129380F8FFFQ38436175-16B5E983-6B8A-436E-886F-95EB649DE878Q38620925-C5423573-E7A1-4E26-82EC-A9EFCA708332Q38730482-EE7B47C6-9EB3-4754-872A-84227DA51D98Q38979271-09CBAD59-F91C-42F8-BA13-CCC10AD4A09E
P2860
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@ast
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@en
type
label
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@ast
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@en
prefLabel
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@ast
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@en
P2860
P1476
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
@en
P2093
Kamran Khodakhah
Karina Alviña
P2860
P304
P356
10.1523/JNEUROSCI.3582-09.2010
P407
P577
2010-05-01T00:00:00Z